Compare American International Group Inc (AIG) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American International Group Inc vs Citius Pharmaceuticals Inc — how do they compare? American International Group Inc trades at $79.57 (market cap $42.98B), while Citius Pharmaceuticals Inc trades at $0.56 (market cap $15.98M). The key difference: American International Group Inc is far larger — about 2689.6× Citius Pharmaceuticals Inc's market cap, and American International Group Inc pays a 2.47% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AIG | CTXR | |
|---|---|---|
Market Cap | $42.98B | $15.98M |
Sector | Financials | Health |
52-Week High | $86.59 | $1.94 |
52-Week Low | $71.89 | $0.53 |
Enterprise Value | $50.68B | $12.19M |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $81.06, up 2.1% today, showing strong momentum with three consecutive quarterly earnings beats. The stock is supported by bullish technical signals and a consensus price target of $88.13. Recent executive appointments and the acquisition of Everest Colombia signal strategic growth initiatives. Revenue stabilized around $26.8B in 2025 with net income margin improving to 11.88%.
Outlook remains positive with earnings growth and expansion in Latin America offering upside potential. Risks include catastrophe exposure and competitive pressures. Analysts are predominantly neutral with 58.5% Hold ratings, suggesting cautious optimism amid solid fundamentals.
CTXR trades at $0.6075, up 5.73% in the last session, with a neutral technical signal and bearish moving averages. The company reported a net loss of $37.43 million for 2025, with a negative net income margin of -823.34%, while generating $5.6 million in revenue in the first half of 2026 from its LYMPHIR launch. Recent news highlights positive Phase 1 data for LYMPHIR presented at ASCO, though earnings have consistently missed expectations.
The outlook remains speculative, with significant upside potential if LYMPHIR gains commercial traction, but high execution risks and persistent losses pose substantial downside. Analyst consensus is strongly bullish at 83.3% buy ratings, reflecting optimism on the drug pipeline, yet investors face dilution risks from recent financing and the challenge of achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
